Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

PET-CT as a predictor of outcome in resectable colorectal liver metastases.

Jones C, Badger SA, Stevenson M, Diamond T, McKie LD, Taylor MA, Wilson RH, Lynch TB.

Eur J Gastroenterol Hepatol. 2014 Apr;26(4):466-72. doi: 10.1097/MEG.0000000000000036.

PMID:
24445726
2.
3.

Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.

Lastoria S, Piccirillo MC, Caracò C, Nasti G, Aloj L, Arrichiello C, de Lutio di Castelguidone E, Tatangelo F, Ottaiano A, Iaffaioli RV, Izzo F, Romano G, Giordano P, Signoriello S, Gallo C, Perrone F.

J Nucl Med. 2013 Dec;54(12):2062-9. doi: 10.2967/jnumed.113.119909. Epub 2013 Oct 17.

4.

The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.

Zerizer I, Al-Nahhas A, Towey D, Tait P, Ariff B, Wasan H, Hatice G, Habib N, Barwick T.

Eur J Nucl Med Mol Imaging. 2012 Sep;39(9):1391-9. doi: 10.1007/s00259-012-2149-1. Epub 2012 May 30.

PMID:
22644713
5.

Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.

Correa-Gallego C, Gavane S, Grewal R, Cercek A, Klimstra DS, Gewirtz AN, Kingham TP, Fong Y, DeMatteo RP, Allen PJ, Jarnagin WR, Kemeny N, D'Angelica MI.

HPB (Oxford). 2015 Jul;17(7):644-50. doi: 10.1111/hpb.12421. Epub 2015 May 23.

6.

Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: an 11-year single-centre study.

John SK, Robinson SM, Rehman S, Harrison B, Vallance A, French JJ, Jaques BC, Charnley RM, Manas DM, White SA.

Dig Surg. 2013;30(4-6):293-301. doi: 10.1159/000354310. Epub 2013 Aug 21.

PMID:
23969407
7.

Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma.

Han JH, Kim DG, Na GH, Kim EY, Lee SH, Hong TH, You YK.

World J Gastroenterol. 2014 Dec 7;20(45):17132-40. doi: 10.3748/wjg.v20.i45.17132.

8.

Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.

Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.

Acad Radiol. 2013 Jan;20(1):32-40. doi: 10.1016/j.acra.2012.07.002. Epub 2012 Sep 19.

PMID:
22999369
9.

Improved long-term survival after resection of colorectal liver metastases following staging with FDG positron emission tomography.

Abbadi RA, Sadat U, Jah A, Praseedom RK, Jamieson NV, Cheow HK, Whitley S, Ford HE, Wilson CB, Harper SJ, Huguet EL.

J Surg Oncol. 2014 Sep;110(3):313-9. doi: 10.1002/jso.23623. Epub 2014 Apr 16.

PMID:
24737685
10.

Treatment and multivariate analysis of colorectal cancer with liver metastasis.

Wang Y, Duan B, Shen C, Wu B, Luo J, Zhao G.

Hepatogastroenterology. 2014 Sep;61(134):1568-73.

PMID:
25436344
11.

Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.

Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):27-38. doi: 10.1007/s00259-011-1934-6. Epub 2011 Sep 23.

PMID:
21946983
12.

Prognostic value and clinical correlations of 18-fluorodeoxyglucose metabolism quantifiers in gastric cancer.

Grabinska K, Pelak M, Wydmanski J, Tukiendorf A, d'Amico A.

World J Gastroenterol. 2015 May 21;21(19):5901-9. doi: 10.3748/wjg.v21.i19.5901.

13.

Is carcino-embryonic antigen useful in the follow-up management of patients with colorectal liver metastases?

Bakalakos EA, Burak WE Jr, Young DC, Martin EW Jr.

Am J Surg. 1999 Jan;177(1):2-6.

PMID:
10037299
14.

Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial.

Moulton CA, Gu CS, Law CH, Tandan VR, Hart R, Quan D, Fairfull Smith RJ, Jalink DW, Husien M, Serrano PE, Hendler AL, Haider MA, Ruo L, Gulenchyn KY, Finch T, Julian JA, Levine MN, Gallinger S.

JAMA. 2014 May 14;311(18):1863-9. doi: 10.1001/jama.2014.3740.

PMID:
24825641
15.

Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver.

Lau LF, Williams DS, Lee ST, Scott AM, Christophi C, Muralidharan V.

Ann Surg Oncol. 2014 Jul;21(7):2420-8. doi: 10.1245/s10434-014-3590-0. Epub 2014 Mar 5.

PMID:
24595797
16.

FDG-PET-CT is effective in selecting patients with poor long term survivals for colorectal liver metastases.

Yip VS, Poston GJ, Fenwick SW, Wieshmann H, Athwal T, Malik HZ.

Eur J Surg Oncol. 2014 Aug;40(8):995-9. doi: 10.1016/j.ejso.2013.10.026. Epub 2013 Nov 15.

PMID:
24290370
18.
19.

Imaging features of colorectal liver metastasis in FDG PET-CT: a retrospective correlative analysis between CT attenuation and FDG uptake.

Au-Yeung AW, Luk WH, Lo AX.

Nucl Med Commun. 2012 Apr;33(4):403-7. doi: 10.1097/MNM.0b013e32834f4d54.

PMID:
22273638
20.

PET-CT accurately predicts the pre-operative characteristics of colorectal hepatic metastases.

Jones C, Badger SA, McKie LD, Diamond T, Taylor MA, Lynch TB.

Eur J Surg Oncol. 2012 Dec;38(12):1184-8. doi: 10.1016/j.ejso.2012.07.001. Epub 2012 Aug 9.

PMID:
22883963

Supplemental Content

Support Center